Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Adakveo (crizanlizumab-tmca) is indicated to reduce the frequency of vaso-occlusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.
• This summary is based on the review of five systematic review(s)/meta-analysis(es). ^[1-5]
• Crizanlizumab reduced the frequency of vaso-occlusive crises (VOCs) by 45% in the SUSTAIN trial and demonstrated a significant reduction compared to placebo (HR 0.55, 95% credible interval 0.43, 0.69), with a p-value of 0.02.
• Crizanlizumab prolonged the median time to the first and second VOC and was associated with a reduction in all-cause hospitalization days (HR 0.58, 95% credible interval 0.50, 0.68).
• Voxelotor significantly increased hemoglobin levels (p=<0.001) and exhibited potential synergy when combined with L-Glutamine, while the combination of voxelotor and crizanlizumab was antagonistic.
• Pain was the most common adverse event reported across all therapies (crizanlizumab, L-Glutamine, voxelotor).
• Crizanlizumab exhibited a safety profile comparable to placebo, with no significant differences in adverse events or serious adverse events.
• There is no population types or subgroups information available in the reviewed studies.